ARQT (Biotechnology) Stock Valuation & Fair Value Quality business at a reasonable price
ARQT (Biotechnology) trades at a blended P/E of 439.7, in line with its historical valuation, with a forward growth estimate of 305.3% and a PEG of 1.44. Analysts' one-year estimates have been hit 20% of the time.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is ARQT overvalued?
At a blended P/E of 439.7, ARQT is broadly in line with its historical valuation, with a PEG of 1.44 on 305.3% forward growth. tickerseer currently rates it quality business at a reasonable price.
What is ARQT's fair value and PEG?
ARQT trades at a blended P/E of 439.7, a PEG of 1.44, and a forward growth estimate of 305.3%.
Has tickerseer's rating of ARQT changed?
tickerseer's rating has been quality business at a reasonable price since 2026-07-31.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.